Trials / Active Not Recruiting
Active Not RecruitingNCT07005713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of BGB-16673 in adults with chronic spontaneous urticaria (CSU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-16673 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-07-19
- Primary completion
- 2026-04-17
- Completion
- 2026-04-17
- First posted
- 2025-06-05
- Last updated
- 2026-02-03
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07005713. Inclusion in this directory is not an endorsement.